

Supplementary information

**Inhibition of late sodium current suppresses calcium-related
ventricular arrhythmias by reducing the phosphorylation of CaMK-
II and sodium channel expressions**

**Xiao-Hong Wei^{1,2}, Shan-Dong Yu^{1,2}, Lu Ren^{1,2}, Si-Hui Huang^{1,2}, Qiao-Mei Yang^{1,2}, Ping
Wang¹, Yan-Peng Chu^{1,2}, Wei Yang^{1,2}, Yan-Sheng Ding^{1,2}, Yong Huo^{1,2,*}, and Lin Wu^{1,2,*}**

¹Department of Cardiology, Peking University First Hospital, Beijing, 100034, China

²Key Laboratory of Molecular Cardiovascular Sciences, Ministry of Education, Beijing, 100191,
China.

*Corresponding authors: Lin Wu, wuepgroup@126.com; and Yong Huo, huoyong@263.net.cn.

Methods

Myocardial ischemia/reperfusion (I/R) model establishment and myocardial infarct size


assessment in rats. To determine the effect of late sodium current inhibitors on a disease model (myocardial ischemia/reperfusion injury) associated with late sodium current, male Sprague-Dawley rats weighing 240-260 g were subjected to left anterior descending coronary artery (LADCA) occlusion by ligation for 30 min followed by reperfusion for 90 min. Animals were divided into three groups: Sham, I/R model, and ranolazine + I/R. Ranolazine (10 μ M) was administered by intravenous for 30 min before ischemia, and was continuously administered till the end of reperfusion at a speed of 1 ml/h.

At the end of reperfusion, the LADCA was re-ligated, and 2 ml of 4% Evans blue (Sigma Aldrich, Missouri, USA) was injected into the right femoral vein via intravenous catheter to delineate the area at risk (AAR). Then the heart was excised at a 5 mm level above the apex cordis and sliced transversely into five sections (1 mm thick). The slices were incubated in 0.375% 2,3,5-triphenyltetrazolium chloride (TTC) (AMRESCO, Ohio, USA) at 37 °C for 15 min to identify the infarct size. AAR, infarct size and left ventricle (LV) were determined using Image-Pro Plus 5.0 software (Media Cybernetic, Maryland, USA).

Results

Eleclazine decreased the reverse use dependence (RUD) effect of Bay K 8644 on left ventricular epi-MAPD₉₀. As shown in Supplementary Fig. S1, eleclazine exhibited similar effect to TTX on Bay K 8644-induced RUD phenomenon of MAPD₉₀. Bay K 8644 (200 nM) prolonged epi-MAPD₉₀ at all stimulation rates (n=5, $P < 0.05$), and the prolongation was greater at longer cycle length (CL)s (e.g., 75.8 ± 4.4 ms at a CL of 2000 ms) than at shorter CLs ($19.6 \pm$


5.2 ms at a CL of 400 ms, $P < 0.05$). In the continued presence of Bay K 8644 in same group of hearts, eleclazine significantly attenuated the RUD of epi-MAPD₉₀, especially at longer CLs (n=5, $P < 0.05$).



Supplementary Figure S1. Effects of eleclazine on the RUD of MAPD₉₀ caused by Bay K 8644. Values of MAPD₉₀ were measured in the absence (Ctrl) and presence of Bay K 8644 (200 nM), Bay K 8644 (200 nM) plus eleclazine (n=5). * $P < 0.05$ vs. cycle length (CL) of 400 ms; # $P < 0.05$ vs. Ctrl at the same CL; † $P < 0.05$ vs. Bay K 8644 alone at the same CL.

Inhibition of late I_{Na} by ranolazine (10 μ M) diminished the infarct size after myocardial I/R.

As shown in Supplementary Fig. S2, ranolazine caused a reduced ratio of infarct size/AAR in hearts treated compared to that from I/R model (Supplementary Fig. S2, (a) and (c)). However, the ratios of AAR/LV were similar in all three groups, indicating similar tension and placement of the ligature across the three groups (Supplementary Fig. S2(b)).



Supplementary Figure S2. Ranolazine (10 μ M) reduced the infarct size in hearts with ischemia/reperfusion (I/R) injury. (a), representative images of Evans blue-TTX staining in Sham, I/R 90 min, and ranolazine plus I/R 90 min. (b) and (c), the statistic results of AAR/LV (b) and Infarct size/AAR (c) among the three groups. AAR: area at risk; LV: left ventricle. $n=3$, * $P < 0.05$ vs. Sham; # $P < 0.05$ vs. I/R 90 min.